CN107519338A - A kind of Chinese medicine composition of external application protection eyesight - Google Patents
A kind of Chinese medicine composition of external application protection eyesight Download PDFInfo
- Publication number
- CN107519338A CN107519338A CN201610462469.6A CN201610462469A CN107519338A CN 107519338 A CN107519338 A CN 107519338A CN 201610462469 A CN201610462469 A CN 201610462469A CN 107519338 A CN107519338 A CN 107519338A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- chinese medicine
- medicine composition
- grass
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 72
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 230000004438 eyesight Effects 0.000 title claims abstract description 6
- 208000024891 symptom Diseases 0.000 claims abstract description 44
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 37
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 36
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 36
- 240000005250 Chrysanthemum indicum Species 0.000 claims abstract description 35
- 235000018959 Chrysanthemum indicum Nutrition 0.000 claims abstract description 35
- 235000005412 red sage Nutrition 0.000 claims abstract description 35
- 244000001632 Acorus gramineus Species 0.000 claims abstract description 34
- 235000013073 Acorus gramineus Nutrition 0.000 claims abstract description 34
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 33
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 33
- 244000246386 Mentha pulegium Species 0.000 claims abstract description 33
- 235000016257 Mentha pulegium Nutrition 0.000 claims abstract description 33
- 235000004357 Mentha x piperita Nutrition 0.000 claims abstract description 33
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 33
- 229940116229 borneol Drugs 0.000 claims abstract description 33
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 33
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 33
- 235000001050 hortel pimenta Nutrition 0.000 claims abstract description 33
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 32
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 32
- 235000015511 Liquidambar orientalis Nutrition 0.000 claims abstract description 32
- 239000004870 Styrax Substances 0.000 claims abstract description 32
- 244000028419 Styrax benzoin Species 0.000 claims abstract description 32
- 235000000126 Styrax benzoin Nutrition 0.000 claims abstract description 32
- 229940041616 menthol Drugs 0.000 claims abstract description 32
- 235000001361 Styrax officinalis Nutrition 0.000 claims abstract description 31
- 229910021538 borax Inorganic materials 0.000 claims abstract description 31
- 235000019382 gum benzoic Nutrition 0.000 claims abstract description 31
- 239000004328 sodium tetraborate Substances 0.000 claims abstract description 31
- 235000010339 sodium tetraborate Nutrition 0.000 claims abstract description 31
- 229940079593 drug Drugs 0.000 claims abstract description 30
- 229940105847 calamine Drugs 0.000 claims abstract description 25
- 229910052864 hemimorphite Inorganic materials 0.000 claims abstract description 25
- 235000014692 zinc oxide Nutrition 0.000 claims abstract description 25
- 239000011787 zinc oxide Substances 0.000 claims abstract description 25
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 claims abstract description 25
- 208000003464 asthenopia Diseases 0.000 claims abstract description 24
- 206010034960 Photophobia Diseases 0.000 claims abstract description 14
- 230000000694 effects Effects 0.000 claims abstract description 12
- 239000000284 extract Substances 0.000 claims description 54
- 241001060310 Styracaceae Species 0.000 claims description 30
- 238000002360 preparation method Methods 0.000 claims description 23
- 238000000605 extraction Methods 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 4
- 101100033673 Mus musculus Ren1 gene Proteins 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000003885 eye ointment Substances 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000002137 ultrasound extraction Methods 0.000 claims description 2
- 244000303379 Styrax officinalis Species 0.000 abstract 1
- 238000004458 analytical method Methods 0.000 description 20
- 238000000034 method Methods 0.000 description 14
- 239000004744 fabric Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 125000004122 cyclic group Chemical group 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- 239000004575 stone Substances 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 7
- 241000628997 Flos Species 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 244000061520 Angelica archangelica Species 0.000 description 5
- 240000004670 Glycyrrhiza echinata Species 0.000 description 5
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 5
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 5
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 5
- 235000001287 Guettarda speciosa Nutrition 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000008034 disappearance Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 229940010454 licorice Drugs 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- -1 tackifier Substances 0.000 description 5
- 239000008188 pellet Substances 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 3
- 235000011613 Pinus brutia Nutrition 0.000 description 3
- 241000018646 Pinus brutia Species 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000029257 vision disease Diseases 0.000 description 3
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 235000017276 Salvia Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000003359 percent control normalization Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- OQUFOZNPBIIJTN-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;sodium Chemical compound [Na].OC(=O)CC(O)(C(O)=O)CC(O)=O OQUFOZNPBIIJTN-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 241000112528 Ligusticum striatum Species 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 101100033674 Mus musculus Ren2 gene Proteins 0.000 description 1
- 241000490567 Pinctada Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NFIYTPYOYDDLGO-UHFFFAOYSA-N phosphoric acid;sodium Chemical compound [Na].OP(O)(O)=O NFIYTPYOYDDLGO-UHFFFAOYSA-N 0.000 description 1
- 238000005554 pickling Methods 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/009—Sachets, pouches characterised by the material or function of the envelope
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of Chinese medicine composition of external application protection eyesight, the bulk drug of the Chinese medicine composition includes：Menthol, storax, styrax, borneol, grass-leaved sweetflag, the red sage root, Radix Angelicae Sinensis, chrysanthemum indicum, mother-of-pearl, borax, cassia seed, the shell of seaear, calamine, peppermint, earthworm, radix glycyrrhizae, Rui Ren.The Chinese medicine composition to alleviate visual fatigue caused by ophthalmospasm, shed tears, photophobia, symptom of aching have significant curative effect.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition of external application protection eyesight, belong to Chinese medicine health-care field.
Background technology
Kopiopia is a kind of ophthalmology common disease, the eye caused by it is dry, eye is puckery, eye it is sour it is swollen, regarding thing
Fuzzy even visual impairment directly affects the work and life of people.Kopiopia is mainly due to people
Watch computer or television screen attentively for a long time, number of winks, which is reduced, causes tears Secretion to reduce,
The neck that people caused by the intense stimulus eyes of fluorescent screen, can be caused is flashed simultaneously, shoulder, first-class position go out
Existing pain, can also trigger various illness in eye.
People are alleviated and treatment eye strain solves usually through dripping eyedrop, but direct contact angle
The mode of film may cause groups of people not tolerate due to the stimulation component in medicament for the eyes, or even produce stimulation.
Massage method can also alleviate eye strain, but can only typically play the effect of respite.
The content of the invention
It is an object of the invention to provide a kind of Chinese medicine composition of external application protection eyesight, the original of said composition
Material medicine includes：Menthol, storax, styrax, borneol, grass-leaved sweetflag, the red sage root, Radix Angelicae Sinensis, chrysanthemum indicum,
Mother-of-pearl, borax, cassia seed, the shell of seaear, calamine, peppermint, earthworm, radix glycyrrhizae, Rui Ren.
In some embodiments, the bulk drug composition of the Chinese medicine composition is：The weight of menthol 0.5~4
Measure part, the parts by weight of storax 2~10, the parts by weight of styrax 1~12, the parts by weight of borneol 6~30, stone Chang
The parts by weight of Pu 6~30, the parts by weight of the red sage root 6~30, the parts by weight of Radix Angelicae Sinensis 2.5~25, the weight of chrysanthemum indicum 2.5~25
Measure part, the parts by weight of mother-of-pearl 2~20, the parts by weight of borax 1~15, the parts by weight of cassia seed 1~15, Shi Jue
Bright 1~12 parts by weight, the parts by weight of calamine 1~12, the parts by weight of peppermint 1~12, the weight of earthworm 1~12
Part, the parts by weight of radix glycyrrhizae 1~12, the parts by weight of Rui Ren 1~10.
Preferably, the bulk drug composition of the Chinese medicine composition is：The parts by weight of menthol 0.8~3, Su He
Fragrant 2~15 parts by weight, the parts by weight of styrax 1.5~10, the parts by weight of borneol 8~25, grass-leaved sweetflag 8~25
Parts by weight, the parts by weight of the red sage root 8~25, the parts by weight of Radix Angelicae Sinensis 3~20, the parts by weight of chrysanthemum indicum 3~20, pearl
Female 2~15 parts by weight, the parts by weight of borax 1.5~12, the parts by weight of cassia seed 1.5~12, the shell of seaear 1.5~10
Parts by weight, the parts by weight of calamine 1.5~10, the parts by weight of peppermint 1.5~10, the parts by weight of earthworm 1.5~10,
The parts by weight of radix glycyrrhizae 1.5~10, the parts by weight of Rui Ren 1.5~7；
It is further preferred that the bulk drug composition of the Chinese medicine composition is：The parts by weight of menthol 1~2.2,
The parts by weight of storax 3~12, the parts by weight of styrax 2~8, the parts by weight of borneol 10~22, grass-leaved sweetflag 10~22
Parts by weight, the parts by weight of the red sage root 10~22, the parts by weight of Radix Angelicae Sinensis 5~18, the parts by weight of chrysanthemum indicum 5~18, treasure
The parts by weight of pearl oyster 3~12, the parts by weight of borax 2~10, the parts by weight of cassia seed 2~10, the weight of the shell of seaear 2~8
Measure part, the parts by weight of calamine 2~8, the parts by weight of peppermint 2~8, the parts by weight of earthworm 2~8, radix glycyrrhizae 2~8
Parts by weight, the parts by weight of Rui Ren 1.8~6；
It is further preferred that the bulk drug composition of the Chinese medicine composition is：The weight of menthol 1.3~1.8
Part, the parts by weight of storax 5~10, the parts by weight of styrax 3~7, the parts by weight of borneol 12~18, grass-leaved sweetflag
12~18 parts by weight, the parts by weight of the red sage root 12~18, the parts by weight of Radix Angelicae Sinensis 7~14, the weight of chrysanthemum indicum 7~14
Part, the parts by weight of mother-of-pearl 5~10, the parts by weight of borax 3~9, the parts by weight of cassia seed 3~9, the shell of seaear 3~7
Parts by weight, the parts by weight of calamine 3~7, the parts by weight of peppermint 3~7, the parts by weight of earthworm 3~7, radix glycyrrhizae 3~7
Parts by weight, the parts by weight of Rui Ren 2~5；
Still more preferably, the bulk drug composition of the Chinese medicine composition is：The parts by weight of menthol 1.5,
The parts by weight of storax 8, the parts by weight of styrax 5, the parts by weight of borneol 15, the parts by weight of grass-leaved sweetflag 15,
The parts by weight of the red sage root 15, the parts by weight of Radix Angelicae Sinensis 10, the parts by weight of chrysanthemum indicum 10, the parts by weight of mother-of-pearl 8, boron
The parts by weight of sand 6, the parts by weight of cassia seed 6, the parts by weight of the shell of seaear 5, the parts by weight of calamine 5, peppermint 5
Parts by weight, the parts by weight of earthworm 5, the parts by weight of radix glycyrrhizae 5, the parts by weight of Rui Ren 3；
Or, the parts by weight of menthol 1.6, the parts by weight of storax 6, the parts by weight of styrax 6, borneol 13
Parts by weight, the parts by weight of grass-leaved sweetflag 16, the parts by weight of the red sage root 13, the parts by weight of Radix Angelicae Sinensis 13, the weight of chrysanthemum indicum 8
Measure part, the parts by weight of mother-of-pearl 9, the parts by weight of borax 4, the parts by weight of cassia seed 8, the weight of the shell of seaear 4
Part, the parts by weight of calamine 6, the parts by weight of peppermint 4, the parts by weight of earthworm 6, the parts by weight of radix glycyrrhizae 4, Rui
The parts by weight of benevolence 4；
Or, the parts by weight of menthol 1.4, the parts by weight of storax 9, the parts by weight of styrax 4, borneol 16
Parts by weight, the parts by weight of grass-leaved sweetflag 13, the parts by weight of the red sage root 16, the parts by weight of Radix Angelicae Sinensis 8, the weight of chrysanthemum indicum 12
Measure part, the parts by weight of mother-of-pearl 6, the parts by weight of borax 8, the parts by weight of cassia seed 4, the weight of the shell of seaear 6
Part, the parts by weight of calamine 4, the parts by weight of peppermint 6, the parts by weight of earthworm 4, the parts by weight of radix glycyrrhizae 6, Rui
The parts by weight of benevolence 2.5.
In some embodiments, the grass-leaved sweetflag in the bulk drug, the red sage root, Radix Angelicae Sinensis, chrysanthemum indicum, certainly
Pine torch, radix glycyrrhizae, Rui Ren, can also extract or active components in addition to being fed intake in the form of crude drug
Form is fed intake, such as Flos Chrysanthemi Indici extract, Salvia root P.E, and the extract or active component are
Each crude drug extracts according to a conventional method to be prepared, and the general extraction methods include decocting extraction, ultrasound
Extraction, seepage pressure effects, Soakage extraction, refluxing extraction, water extract-alcohol precipitation etc., Extraction solvent include water or
40~80% ethanol solutions.
In some embodiments, routinely external preparation is made in preparation process to the Chinese medicine composition；Institute
Stating external preparation includes liquid preparation, ophthalmically acceptable semisolid preparation, ophthalmically acceptable solid pharmaceutical preparation；It is further described
External preparation include be easy to ultrasonic atomizatio be administered preparation (liquid formulation or solid formulation), ocular inserts,
Gel for eye, Eye ointments, ophthalmically acceptable cream, ophthalmically acceptable liposome, ophthalmically acceptable microparticle formulation, stick preparation
Deng.
To enable formulation of the present invention to realize, need to be added when preparing these formulations pharmaceutically acceptable
Additive, such as buffer, isotonic agent, preservative, cosolvent, pH adjusting agent, tackifier, chelating
Agent etc..In above-mentioned additive, PB, borate buffer, lemon can be used as buffer
Lemon hydrochlorate buffer, tartarate buffer, acetate buffer, amino acid etc.；As isotonic agent example
Such as D-sorbite, glucose, the polyalcohol such as mannitol carbohydrate, glycerine, polyethylene glycol, propane diols
Salts such as class, sodium chloride etc.；It can use benzalkonium chloride, benzethonium chloride, glucose pickling must as preservative
Thailand, methyl p-hydroxybenzoate, thiomersalate, methaform etc.；As cosolvent such as ring
The surfaces such as the water soluble polymer such as dextrin class and its derivative, polyvinylpyrrolidone, polyoxyethylene sorbitan monoleate
Activating agent etc.；As tackifier such as hydroxyethyl cellulose, hydroxypropyl cellulose, methylcellulose, hydroxyl
Propyl methocel, carboxymethyl cellulose and its salt etc.；As chelating agent such as edetate sodium, citric acid
Sodium, condensed phosphoric acid sodium etc..
Embodiment
Embodiment 1
Menthol 1.5g, storax 8g, styrax 5g, borneol 15g, grass-leaved sweetflag 15g, red sage root 15g,
Radix Angelicae Sinensis 10g, chrysanthemum indicum 10g, mother-of-pearl 8g, borax 6g, cassia seed 6g, shell of seaear 5g, stove are sweet
Stone 5g, peppermint 5g, earthworm 5g, radix glycyrrhizae 5g, Rui Ren 3g；
Preparation method：After each bulk drug is crushed, it is well mixed, is packaged in made of chemical fabric in cyclic bags.
Application method：The Chinese medicine composition health care ring is externally applied to around eye socket (can be with CN
" double mists regard medicine Vacuum Pressure Swing instrument for eye disease " disclosed in 2339193Y utility model patents is common
Use, the Chinese medicine composition health care ring is put into " double mists regard medicine Vacuum Pressure Swing instrument for eye disease " picture frame
It is interior), patient closes eyes, Chinese medicine composition health care ring is worn in eye, retains more than 20 minutes.
Embodiment 2
Menthol 1.6g, storax 6g, styrax 6g, borneol 13g, grass-leaved sweetflag 16g, red sage root 13g,
Radix Angelicae Sinensis 13g, chrysanthemum indicum 8g, mother-of-pearl 9g, borax 4g, cassia seed 8g, shell of seaear 4g, calamine
6g, peppermint 4g, earthworm 6g, radix glycyrrhizae 4g, Rui Ren 4g；
Preparation method：After each bulk drug is crushed, it is well mixed, is packaged in made of chemical fabric in cyclic bags.
Application method：With embodiment 1.
Embodiment 3
Menthol 1.4g, storax 9g, styrax 4g, borneol 16g, grass-leaved sweetflag 13g, red sage root 16g,
Radix Angelicae Sinensis 8g, chrysanthemum indicum 12g, mother-of-pearl 6g, borax 8g, cassia seed 4g, shell of seaear 6g, calamine
4g, peppermint 6g, earthworm 4g, radix glycyrrhizae 6g, Rui Ren 2.5g；
Preparation method：After each bulk drug is crushed, it is well mixed, is packaged in made of chemical fabric in cyclic bags.
Application method：With embodiment 1.
Embodiment 4
Menthol 1.3g, storax 10g, styrax 3g, borneol 18g, grass-leaved sweetflag 12g, red sage root 18g,
Radix Angelicae Sinensis 7g, chrysanthemum indicum 14g, mother-of-pearl 5g, borax 9g, cassia seed 3g, shell of seaear 7g, calamine
3g, peppermint 7g, earthworm 3g, radix glycyrrhizae 7g, Rui Ren 2g；
Preparation method：Grass-leaved sweetflag, the red sage root, Radix Angelicae Sinensis, chrysanthemum indicum, cassia seed, radix glycyrrhizae, Rui Ren is taken to add decocting
Boil, filter, merge extract solution, be dried under reduced pressure to obtain extract medicinal extract, it is standby；Mixed with other raw materials
Crush, be packaged in made of chemical fabric in cyclic bags after even.
Application method：With embodiment 1.
Embodiment 5
Menthol 1.8g, storax 5g, styrax 7g, borneol 12g, grass-leaved sweetflag 18g, red sage root 12g,
Radix Angelicae Sinensis 14g, chrysanthemum indicum 7g, mother-of-pearl 10g, borax 3g, cassia seed 9g, shell of seaear 3g, stove are sweet
Stone 7g, peppermint 3g, earthworm 7g, radix glycyrrhizae 3g, Rui Ren 5g；
Preparation method：Grass-leaved sweetflag, the red sage root, Radix Angelicae Sinensis, chrysanthemum indicum, cassia seed, radix glycyrrhizae, Rui Ren is taken to add 50%
Alcohol reflux extracts, and merges extract solution, filtration, filtrate concentration, 15min is centrifuged with 3000r/min,
Supernatant is taken, is concentrated, is dried, is crushed after being mixed with other raw materials, is packaged in ring made of chemical fabric
In shape bag.
Application method：With embodiment 1.
Embodiment 6
Menthol 2.2g, storax 3g, styrax 8g, borneol 10g, grass-leaved sweetflag 22g, red sage root 10g,
Radix Angelicae Sinensis 18g, chrysanthemum indicum 5g, mother-of-pearl 12g, borax 2g, cassia seed 10g, shell of seaear 2g, stove are sweet
Stone 8g, peppermint 2g, earthworm 8g, radix glycyrrhizae 2g, Rui Ren 6g；
Preparation method：Grass-leaved sweetflag, the red sage root, Radix Angelicae Sinensis, chrysanthemum indicum, cassia seed, radix glycyrrhizae, Rui Ren is taken to add 60% second
Alcohol reflux extracts, and filtration, merges extract solution, is dried under reduced pressure to obtain extract medicinal extract, is mixed with other raw materials
After crush, be packaged in made of chemical fabric in cyclic bags.
Application method：With embodiment 1.
Embodiment 7
Menthol 1g, storax 12g, styrax 2g, borneol 22g, grass-leaved sweetflag 10g, red sage root 22g,
Radix Angelicae Sinensis 5g, chrysanthemum indicum 18g, mother-of-pearl 3g, borax 10g, cassia seed 2g, shell of seaear 8g, stove are sweet
Stone 2g, peppermint 8g, earthworm 2g, radix glycyrrhizae 8g, Rui Ren 1.8g；
Preparation method：Grass-leaved sweetflag, the red sage root, Radix Angelicae Sinensis, chrysanthemum indicum, cassia seed, radix glycyrrhizae, Rui Ren is taken to add water to cook,
Filtration, merge extract solution, be dried under reduced pressure to obtain extract medicinal extract, mixed with other raw materials, add normal
Externally used paste is made in rule auxiliary material.
Embodiment 8
Menthol 3g, storax 2g, styrax 10g, borneol 8g, grass-leaved sweetflag 25g, red sage root 8g,
Radix Angelicae Sinensis 20g, chrysanthemum indicum 3g, mother-of-pearl 15g, borax 1.5g, cassia seed 12g, shell of seaear 1.5g,
Calamine 10g, peppermint 1.5g, earthworm 10g, radix glycyrrhizae 1.5g, Rui Ren 7g；
Preparation method：Grass-leaved sweetflag, the red sage root, Radix Angelicae Sinensis, chrysanthemum indicum, cassia seed, radix glycyrrhizae, Rui Ren is taken to add water to cook,
Filtration, merge extract solution, be dried under reduced pressure to obtain extract medicinal extract, mixed with other raw materials, add normal
External use plaster is made in rule auxiliary material.
Embodiment 9
Menthol 0.8g, storax 15g, styrax 1.5g, borneol 25g, grass-leaved sweetflag 8g, red sage root 25g,
Radix Angelicae Sinensis 3g, chrysanthemum indicum 20g, mother-of-pearl 2g, borax 12g, cassia seed 1.5g, shell of seaear 10g, stove
Sweet stone 1.5g, peppermint 10g, earthworm 1.5g, radix glycyrrhizae 10g, Rui Ren 1.5g；Preparation method and application method are same
Embodiment 1.
Embodiment 10
Menthol 0.5g, storax 10g, styrax 1g, borneol 15g, grass-leaved sweetflag 6g, red sage root 16g,
Radix Angelicae Sinensis 2.5g, chrysanthemum indicum 25g, mother-of-pearl 2g, borax 15g, cassia seed 1g, shell of seaear 12g, stove
Sweet stone 1g, peppermint 12g, earthworm 1g, radix glycyrrhizae 10g, Rui Ren 1g；Preparation method and the same embodiment of application method
1。
Embodiment 11
Menthol 4g, storax 2g, styrax 12g, borneol 6g, grass-leaved sweetflag 30g, red sage root 6g,
Radix Angelicae Sinensis 25g, chrysanthemum indicum 2.5g, mother-of-pearl 20g, borax 1g, cassia seed 15g, shell of seaear 1g, stove
Sweet stone 12g, peppermint 1g, earthworm 12g, radix glycyrrhizae 1g, Rui Ren 10g；Preparation method and application method are the same as implementation
Example 1.
Embodiment 12
Menthol 1.5g, storax 8g, styrax 5g, borneol 15g, Rhizoma Acori Graminei extract 15g, pellet
Conopsea extraction 15g, angelica extract 10g, Flos Chrysanthemi Indici extract 10g, mother-of-pearl 8g, borax 6g,
Cassia seed extract 6g, shell of seaear 5g, calamine 5g, peppermint 5g, earthworm 5g, licorice
5g, Rui Ren extract 3g；
After each bulk drug is crushed, it is well mixed, is packaged in made of chemical fabric in cyclic bags.
Wherein, each extract is respectively the water extract of each bulk drug.
Embodiment 13
Menthol 1.6g, storax 6g, styrax 6g, borneol 13g, Rhizoma Acori Graminei extract 16g, pellet
Conopsea extraction 13g, angelica extract 13g, Flos Chrysanthemi Indici extract 8g, mother-of-pearl 9g, borax 4g, certainly
Pine torch extract 8g, shell of seaear 4g, calamine 6g, peppermint 4g, earthworm 6g, licorice 4g,
Rui Ren extracts 4g；
After each bulk drug is crushed, it is well mixed, is packaged in made of chemical fabric in cyclic bags；
Wherein, each extract is respectively 70% ethanol extract of each bulk drug.
Embodiment 14
Menthol 1.4g, storax 9g, styrax 4g, borneol 16g, Rhizoma Acori Graminei extract 13g, pellet
Conopsea extraction 16g, angelica extract 8g, Flos Chrysanthemi Indici extract 12g, mother-of-pearl 6g, borax 8g, certainly
Pine torch extract 4g, shell of seaear 6g, calamine 4g, peppermint 6g, earthworm 4g, licorice 6g,
Rui Ren extracts 2.5g；
After each bulk drug is crushed, it is well mixed, is packaged in made of chemical fabric in cyclic bags；
Wherein, each extract is respectively that to add ethanol to alcohol content after the extraction of each bulk drug water be 50%
Take the extract obtained after ethanol filtering and concentrating.
Embodiment 15
Menthol 1.3g, storax 10g, styrax 3g, borneol 18g, Rhizoma Acori Graminei extract 12g,
Salvia root P.E 18g, angelica extract 7g, Flos Chrysanthemi Indici extract 14g, mother-of-pearl 5g, borax 9g,
Cassia seed extract 3g, shell of seaear 7g, calamine 3g, peppermint 7g, earthworm 3g, licorice
7g, Rui Ren extract 2g；
Each extract is respectively the water extract of each bulk drug；
After each bulk drug is crushed, it is well mixed, is packaged in made of chemical fabric in cyclic bags.
Embodiment 16
Menthol 1.8g, storax 5g, styrax 7g, borneol 12g, Rhizoma Acori Graminei extract 18g, pellet
Conopsea extraction 12g, angelica extract 14g, Flos Chrysanthemi Indici extract 7g, mother-of-pearl 10g, borax 3g,
Cassia seed extract 9g, shell of seaear 3g, calamine 7g, peppermint 3g, earthworm 7g, licorice
3g, Rui Ren extract 5g；
Wherein, each extract is respectively 90% ethanol extract of each bulk drug.
After each bulk drug is crushed, it is well mixed, is packaged in made of chemical fabric in cyclic bags.
Comparative examples
Borneol 15g, grass-leaved sweetflag 15g, red sage root 15g, Radix Angelicae Sinensis 10g, chrysanthemum indicum 10g, mother-of-pearl 8g,
Shell of seaear 8g, peppermint 5g, earthworm 5g, radix glycyrrhizae 5g, Rui Ren 8g, Ligusticum wallichii 8g, illiteracy flower 12g, radix scutellariae
6g, golden cypress 6g, fruit of Chinese wolfberry 6g, safflower 6g；
Preparation method and application method are the same as embodiment 1.
Effect experimental examples 1
72 people at age 18-65 year are selected, clinical general information is shown in Table 1, is stranded with vision disorder, eye
Tired, photophobia, ache, shed tears, entering in the crowd of visual fatigue symptom such as foreign body sensation, the dry and astringent, ophthalmospasm of eye
Row continues to use the Chinese traditional medicine composition composition powders in 30 days.Because the 18-65 year Gao Fa Nian Ling section for visual fatigue,
There is relatively good compliance.
1 72 visual fatigue patient clinical general information of table
72 patient's stochastic averaginas are divided into 2 groups, a group echo is experimental group (using embodiment 1
Prescription), another group echo is control group (using placebo), experimental group and control group patient clinical one
As data be shown in Table 2.
The experimental group of table 2 and control group visual fatigue patient clinical general information
The Chinese medicine composition health care ring is worn in eye by the application method of embodiment 1, is retained more than 20 minutes,
3 times a day, 30 days as one therapeutic course.Testing site is recorded respectively：One day first before treatment, treat
The improvement situation that 15 (± 1) days, 30 (± 2) days for the treatment of observe the symptoms with sign respectively, and result is remembered
Record, it is efficient with healing+effective+effective case load statistics, judge clinical improvementses result.
Improve the evaluation criterion for alleviating visual fatigue：
Recovery from illness：Symptom disappears or basic disappearance, symptom integral reduce more than 90%；
It is effective：Symptom is obviously improved, and symptom integral reduces 60%-89%；
Effectively：Symptom take a favorable turn, and symptom integral reduces 30%-59%；
It is invalid：Symptom is not improved, even aggravating, symptom integral reduces 30%.
With recovery from illness+effective+effective case load statistics total effective rate.
Evaluation method：
The improvement of symptom is alleviated and passes through clinical test, observation, photophobia, aches, sheds tears, ophthalmospasm etc.
4 indexs, each treatment is made it is light, in, the quantitative criteria of weight, carry out statistical evaluation, Specific amounts
Change standard is shown in " visual fatigue symptom weight hierarchical table " (table 3).
The visual fatigue symptom weight hierarchical table of table 3
| 0 point | 2 points (light) | 4 points (in) | 6 points of (weight)s | |
| Photophobia | Nothing | Photophobia eye to be narrowed | Photophobia narrows eye | Photophobia dare not open eyes |
| Ache | Nothing | Ache indistinctly | Persistently ache | Ache unbearably |
| Shed tears | Nothing | Shed tears less | Shed tears obvious | Shed tears more than |
| Ophthalmospasm | Nothing | Occasionally there is eyelid bounce | Continue eyelid bounce | Serious bounce can not open |
Calculation formula：【Integrated before (being integrated before treatment after integration-treatment)/treatment】* 100%
Statistical processing methods and evaluation method
1st, statistical method
Analyzed using EXCEL.Descriptive statistical analysis, technical indicator are described with frequency table, percentage；
Measuring index is described with mean, standard deviation.
Before and after treatment and experimental group and control group comparative analysis, quantitative data meet normal distribution pairing
T is examined, and does not meet normal distribution Wilcoxon signed rank sum tests, using P≤0.05 as there is statistics
Learn meaning.
2nd, evaluation method
Observation photophobia, ache, shed tears, 4 indexs such as ophthalmospasm, according to symptom it is light, in, weight
Change standard and observe and record result, carry out statistical appraisal.
Clinical test results
1 efficacy evaluation result, is shown in Table 4
The function of table 4 improves efficacy evaluation analysis
| Group | Number of cases | Recovery from illness | It is effective | Effectively | It is invalid | Total effective rate |
| Experimental group | 36 | 3(8.33) | 27(75) | 6(16.67) | 0(0) | 100% |
| Control group | 36 | 0(0) | 3(8.33) | 13(36.11) | 20(55.56) | 44.44% |
2 experimental groups and the pretherapy and post-treatment t check analyses of control group, the results are shown in Table 5.
The experimental group of table 5 and the analysis of control group total mark
From result above it can be found that the experimental group and control group that are randomly assigned each symptom before being treated
There was no significant difference；Experimental group and there is significant difference to a group photograph symptom integral after the treatment；Prove this hair
The significant effect that bright Chinese prescription alleviates 4 kinds of visual fatigue symptoms is better than placebo, has to kopiopia aobvious
The therapeutic effect of work.
The t check analyses of 3 experimental groups and each symptom of control group, the results are shown in Table 6.
The t check analyses of the experimental group of table 6 and each symptom of control group
The distribution situation of experimental group and each symptom of control group is divided and ruled before treating, disappeared after treatment with each symptom
Rate carries out t check analyses, the results are shown in Table 7：
The distribution situation t check analyses of the experimental group of table 7 and each symptom of control group
| T Stat | P | |
| Before treatment | 0 | 1 |
| After treatment | -5.478 | 0.0021 |
| Disappearance rate | 17.223 | 0.0009 |
From result above it can be found that the experimental group and control group that are randomly assigned each symptom before being treated
There was no significant difference；(including disappearance rate) experimental group and there is significant difference to a group photograph after the treatment；Card
The significant effect that bright prescription alleviates 4 kinds of visual fatigue symptoms is better than placebo.
3 symptom analysis, the results are shown in Table 8：
Each symptom t check analyses after the experimental group of table 8 and control group treatment
| Symptom | T Stat | P |
| Ophthalmospasm | -1.269 | 0.021 |
| Shed tears | -1.332 | 0.019 |
| Photophobia | -1.160 | 0.025 |
| Ache | -1.834 | 0.031 |
Experimental group and control group are subjected to t check analyses to each symptom after treatment respectively, are as a result eye convulsion
Contraction, shed tears, photophobia, four indexs such as ache have significant difference；Prove prescription of the present invention for this
The remission effect of four kinds of visual fatigues is superior to placebo.
Effect experimental examples 2
60 people at age 18-65 year are selected, clinical general information is shown in Table 9, is stranded with vision disorder, eye
Tired, photophobia, ache, shed tears, entering in the crowd of visual fatigue symptom such as foreign body sensation, the dry and astringent, ophthalmospasm of eye
Row continues to use the Chinese medicine composition in 30 days.Because the 18-65 year Gao Fa Nian Ling section for visual fatigue, have
Relatively good compliance.
9 60 visual fatigue patient clinical general information of table
60 patient's stochastic averaginas are divided into 2 groups, a group echo is experimental group (using embodiment 1
Prescription), another group echo is the control group prescription of comparative examples (use), experimental group and control group
Patient clinical general information is shown in Table 10.
10 experimental group of table, 30 visual fatigue patient clinical general information
The prescription of embodiment 1 and comparative examples is prepared into health care ring and worn by the application method of embodiment 1
In eye, retain more than 20 minutes, 3 times a day, 30 days as one therapeutic course.Record and test respectively
Point：One day first before treatment, 15 (± 1) days for the treatment of, treat 30 (± 2) days and observe the symptoms respectively and body
The improvement situation of sign, and result is recorded, it is efficient with healing+effective+effective case load statistics, sentence
Determine clinical improvementses result.
Improve the evaluation criterion for alleviating visual fatigue, evaluation method, calculation formula, statistical processing methods and comment
Valency method is the same as effect experimental examples 1.
Clinical test results
1 efficacy evaluation result, is shown in Table 11
The function of table 11 improves efficacy evaluation analysis
| Group | Number of cases | Recovery from illness | It is effective | Effectively | It is invalid | Total effective rate |
| Experimental group | 30 | 2(6.67) | 25(83.33) | 3(10.00) | 0(0) | 100% |
| Control group | 30 | 1(3.33) | 22(73.33) | 7(23.34) | 0(0) | 100% |
2 experimental groups and the pretherapy and post-treatment t check analyses of control group, the results are shown in Table 12.
The experimental group of table 12 and the analysis of control group total mark
Analyzed compared with pre-treatment using paired t-test after experimental group and control group treatment, p value is respectively less than
0.05, show that two kinds of prescriptions are effective for more than treatment four kinds of symptoms.
The t check analyses of 2 experimental groups and each symptom of control group, the results are shown in Table 13.
The t check analyses of the experimental group of table 13 and each symptom of control group
The distribution situation of experimental group and each symptom of control group is divided and ruled before treating, disappeared after treatment with each symptom
Rate carries out t check analyses, the results are shown in Table 14：
The distribution situation t check analyses of the experimental group of table 14 and each symptom of control group
| T Stat | P | |
| Before treatment | 0 | 1 |
| After treatment | -8.467 | 0.0033 |
| Disappearance rate | 14.216 | 0.0007 |
From result above it can be found that the experimental group and control group that are randomly assigned each symptom before being treated
There was no significant difference；(including disappearance rate) experimental group and there is significant difference to a group photograph after the treatment；Card
Bright prescription of the present invention alleviates the significant effect of 4 kinds of visual fatigue symptoms better than control prescription.
3 symptom analysis, the results are shown in Table 15：
Each symptom t check analyses after the experimental group of table 15 and control group treatment
| Symptom | T Stat | P |
| Ophthalmospasm | -2.124 | 0.042 |
| Shed tears | -2.386 | 0.021 |
| Photophobia | -2.283 | 0.030 |
| Ache | -2.189 | 0.037 |
Experimental group and control group are subjected to t check analyses to each symptom after treatment respectively, are as a result eye convulsion
Contraction, shed tears, photophobia, four indexs such as ache have significant difference；Prove prescription of the present invention for this
The remission effect of four kinds of visual fatigues is superior to compare prescription.
Claims (10)
1. a kind of Chinese medicine composition of external application protection eyesight, it is characterised in that the bulk drug of the Chinese medicine composition includes：Menthol, storax, styrax, borneol, grass-leaved sweetflag, the red sage root, Radix Angelicae Sinensis, chrysanthemum indicum, mother-of-pearl, borax, cassia seed, the shell of seaear, calamine, peppermint, earthworm, radix glycyrrhizae, Rui Ren.
2. Chinese medicine composition as claimed in claim 1, it is characterised in that the bulk drug of the Chinese medicine composition, which forms, is：The parts by weight of menthol 0.5~4, the parts by weight of storax 2~10, the parts by weight of styrax 1~12, the parts by weight of borneol 6~30, the parts by weight of grass-leaved sweetflag 6~30, the parts by weight of the red sage root 6~30, the parts by weight of Radix Angelicae Sinensis 2.5~25, the parts by weight of chrysanthemum indicum 2.5~25, the parts by weight of mother-of-pearl 2~20, the parts by weight of borax 1~15, the parts by weight of cassia seed 1~15, the parts by weight of the shell of seaear 1~12, the parts by weight of calamine 1~12, the parts by weight of peppermint 1~12, the parts by weight of earthworm 1~12, the parts by weight of radix glycyrrhizae 1~12, the parts by weight of Rui Ren 1~10.
3. Chinese medicine composition as claimed in claim 1, it is characterised in that the bulk drug of the Chinese medicine composition, which forms, is：The parts by weight of menthol 0.8~3, the parts by weight of storax 2~15, the parts by weight of styrax 1.5~10, the parts by weight of borneol 8~25, the parts by weight of grass-leaved sweetflag 8~25, the parts by weight of the red sage root 8~25, the parts by weight of Radix Angelicae Sinensis 3~20, the parts by weight of chrysanthemum indicum 3~20, the parts by weight of mother-of-pearl 2~15, the parts by weight of borax 1.5~12, the parts by weight of cassia seed 1.5~12, the parts by weight of the shell of seaear 1.5~10, the parts by weight of calamine 1.5~10, the parts by weight of peppermint 1.5~10, the parts by weight of earthworm 1.5~10, the parts by weight of radix glycyrrhizae 1.5~10, the parts by weight of Rui Ren 1.5~7.
4. Chinese medicine composition as claimed in claim 1, it is characterised in that the bulk drug of the Chinese medicine composition, which forms, is：The parts by weight of menthol 1~2.2, the parts by weight of storax 3~12, the parts by weight of styrax 2~8, the parts by weight of borneol 10~22, the parts by weight of grass-leaved sweetflag 10~22, the parts by weight of the red sage root 10~22, the parts by weight of Radix Angelicae Sinensis 5~18, the parts by weight of chrysanthemum indicum 5~18, the parts by weight of mother-of-pearl 3~12, the parts by weight of borax 2~10, the parts by weight of cassia seed 2~10, the parts by weight of the shell of seaear 2~8, the parts by weight of calamine 2~8, the parts by weight of peppermint 2~8, the parts by weight of earthworm 2~8, the parts by weight of radix glycyrrhizae 2~8, the parts by weight of Rui Ren 1.8~6.
5. Chinese medicine composition as claimed in claim 1, it is characterised in that the bulk drug of the Chinese medicine composition, which forms, is：The parts by weight of menthol 1.5, the parts by weight of storax 8, the parts by weight of styrax 5, the parts by weight of borneol 15, the parts by weight of grass-leaved sweetflag 15, the parts by weight of the red sage root 15, the parts by weight of Radix Angelicae Sinensis 10, the parts by weight of chrysanthemum indicum 10, the parts by weight of mother-of-pearl 8, the parts by weight of borax 6, the parts by weight of cassia seed 6, the parts by weight of the shell of seaear 5, the parts by weight of calamine 5, the parts by weight of peppermint 5, the parts by weight of earthworm 5, the parts by weight of radix glycyrrhizae 5, the parts by weight of Rui Ren 3；
Or, the parts by weight of menthol 1.6, the parts by weight of storax 6, the parts by weight of styrax 6, the parts by weight of borneol 13, the parts by weight of grass-leaved sweetflag 16, the parts by weight of the red sage root 13, the parts by weight of Radix Angelicae Sinensis 13, the parts by weight of chrysanthemum indicum 8, the parts by weight of mother-of-pearl 9, the parts by weight of borax 4, the parts by weight of cassia seed 8, the parts by weight of the shell of seaear 4, the parts by weight of calamine 6, the parts by weight of peppermint 4, the parts by weight of earthworm 6, the parts by weight of radix glycyrrhizae 4, the parts by weight of Rui Ren 4；
Or, the parts by weight of menthol 1.4, the parts by weight of storax 9, the parts by weight of styrax 4, the parts by weight of borneol 16, the parts by weight of grass-leaved sweetflag 13, the parts by weight of the red sage root 16, the parts by weight of Radix Angelicae Sinensis 8, the parts by weight of chrysanthemum indicum 12, the parts by weight of mother-of-pearl 6, the parts by weight of borax 8, the parts by weight of cassia seed 4, the parts by weight of the shell of seaear 6, the parts by weight of calamine 4, the parts by weight of peppermint 6, the parts by weight of earthworm 4, the parts by weight of radix glycyrrhizae 6, the parts by weight of Rui Ren 2.5.
6. the Chinese medicine composition as described in any one of Claims 1 to 5, characterized in that, routinely preparation process is prepared into the preparation of ultrasonic atomizatio administration, ocular inserts, gel for eye, Eye ointments, ophthalmically acceptable cream, ophthalmically acceptable liposome, ophthalmically acceptable microparticle formulation or sticks preparation the Chinese medicine composition.
7. the Chinese medicine composition as described in any one of Claims 1 to 5, it is characterised in that grass-leaved sweetflag, the red sage root, Radix Angelicae Sinensis, chrysanthemum indicum, cassia seed, radix glycyrrhizae, Rui Ren in the bulk drug are fed intake in the form of crude drug or fed intake in the form of extract or active component.
8. Chinese medicine composition as claimed in claim 7, it is characterized in that, the extract or active component are extracted and are prepared according to a conventional method for each crude drug, the general extraction methods, which include decoction extraction, ultrasonic extraction, seepage pressure effects, Soakage extraction, refluxing extraction or water extract-alcohol precipitation, Extraction solvent, includes water or 40~80% ethanol solutions.
9. the Chinese medicine composition as described in any one of Claims 1 to 5 is preparing the application in alleviating visual fatigue medicine.
10. application as claimed in claim 9, it is characterised in that the Chinese medicine composition prepare alleviate ophthalmospasm caused by visual fatigue, shed tears, photophobia, ache symptom medicine in application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610462469.6A CN107519338A (en) | 2016-06-22 | 2016-06-22 | A kind of Chinese medicine composition of external application protection eyesight |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610462469.6A CN107519338A (en) | 2016-06-22 | 2016-06-22 | A kind of Chinese medicine composition of external application protection eyesight |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107519338A true CN107519338A (en) | 2017-12-29 |
Family
ID=60734472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610462469.6A Pending CN107519338A (en) | 2016-06-22 | 2016-06-22 | A kind of Chinese medicine composition of external application protection eyesight |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107519338A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115282218A (en) * | 2022-06-28 | 2022-11-04 | 深圳市艾普生物科技有限公司 | Herbal atomized composition for relieving eye fatigue and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006193521A (en) * | 2004-12-17 | 2006-07-27 | Rohto Pharmaceut Co Ltd | Composition for ophthalmology |
| CN101843662A (en) * | 2010-05-28 | 2010-09-29 | 郑州市新视明科技工程有限公司 | Chinese medicinal composition for preventing and treating asthenopia |
| CN102106977A (en) * | 2009-12-24 | 2011-06-29 | 孟繁英 | Externally-applied sturdy vision eyeshield liquid medicine for preventing and treating oculopathy |
| CN103285078A (en) * | 2013-05-31 | 2013-09-11 | 吴克 | Comfortable cream |
| CN103933124A (en) * | 2014-03-27 | 2014-07-23 | 郑州市新视明科技工程有限公司 | Traditional Chinese medicine eye paster for alleviating eyesight fatigue and preparation technology thereof |
| CN104383168A (en) * | 2014-11-03 | 2015-03-04 | 王青年 | Traditional Chinese medicine unguent for improving eyesight and preparation method thereof |
-
2016
- 2016-06-22 CN CN201610462469.6A patent/CN107519338A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006193521A (en) * | 2004-12-17 | 2006-07-27 | Rohto Pharmaceut Co Ltd | Composition for ophthalmology |
| CN102106977A (en) * | 2009-12-24 | 2011-06-29 | 孟繁英 | Externally-applied sturdy vision eyeshield liquid medicine for preventing and treating oculopathy |
| CN101843662A (en) * | 2010-05-28 | 2010-09-29 | 郑州市新视明科技工程有限公司 | Chinese medicinal composition for preventing and treating asthenopia |
| CN103285078A (en) * | 2013-05-31 | 2013-09-11 | 吴克 | Comfortable cream |
| CN103933124A (en) * | 2014-03-27 | 2014-07-23 | 郑州市新视明科技工程有限公司 | Traditional Chinese medicine eye paster for alleviating eyesight fatigue and preparation technology thereof |
| CN104383168A (en) * | 2014-11-03 | 2015-03-04 | 王青年 | Traditional Chinese medicine unguent for improving eyesight and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 孙世光: "《新编医院药学》", 31 March 2010, 军事医学科学出版社 * |
| 张仁俊: "《实用眼科药物学》", 30 September 2015, 人民军医出版社 * |
| 李向荣: "《药剂学》", 28 February 2010, 浙江大学出版社 * |
| 杨贵舫等: "角膜硷烧伤早期治疗的实验", 《内蒙古医学杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115282218A (en) * | 2022-06-28 | 2022-11-04 | 深圳市艾普生物科技有限公司 | Herbal atomized composition for relieving eye fatigue and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104274383A (en) | Composition for promoting skin compliance and active ingredient absorption of eye wet compressing agent | |
| CN107510736A (en) | The Chinese medicine composition of eye strain is alleviated in a kind of external application | |
| CN102698079A (en) | Medicine composition for treating xerophthalmia and preparation method and application thereof | |
| CN109200196B (en) | Dendrobium alkaloid eye patch and preparation method thereof | |
| CN102258742B (en) | Chinese medicinal medicine composition for treating depression and preparation method thereof | |
| CN102085334B (en) | Traditional Chinese medicine preparation for treating atrophic glossitis and preparation method thereof | |
| CN107519338A (en) | A kind of Chinese medicine composition of external application protection eyesight | |
| CN115957270A (en) | Externally applied medicine for treating herpes zoster | |
| CN103520392B (en) | A traditional Chinese medicine composition for treating dry eye and preparation method thereof | |
| CN107648397B (en) | Traditional Chinese medicine composition for treating liver-kidney yin deficiency and preparation method and application thereof | |
| CN100428944C (en) | Compound traditional Chinese medicine for improving eyesight and its prepn. method | |
| CN105833043A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating primary hypertension | |
| CN105343551A (en) | Medicine composition for treating sicca syndrome and preparation method and application of medicine composition | |
| CN105535169A (en) | Method for preparing medicine composition for treating xerophthalmia | |
| CN104547309A (en) | Traditional Chinese medicine composition for removing chloasma, and preparation method and application thereof | |
| CN104324139B (en) | A kind of pharmaceutical composition treating xerophthalmia | |
| CN115040600B (en) | Traditional Chinese medicine composition for treating scalp psoriasis | |
| CN106421198A (en) | Novel application of Qiming (fruit of Chinese wolfberry and semen cassiae) traditional Chinese medicinal composition | |
| CN106581445A (en) | Traditional Chinese medicine prescription for treating diabetic retinopathy | |
| CN108175818B (en) | A kind of traditional Chinese medicine composition for treating glaucoma and its preparation method and use | |
| CN106177102A (en) | A kind of Chinese medicine composition treating xerophthalmia | |
| CN105012751A (en) | Traditional Chinese medicine composition for treating prosopalgia generated after acoustic neuroma operation | |
| CN105395710A (en) | Folium artemisiae argyi-containing traditional Chinese medicine preparation for treating fundus hemorrhage and preparing method thereof | |
| WO2023098776A1 (en) | Use of traditional chinese medicine composition in preparation of medication for treating neuritis | |
| CN118436723A (en) | External traditional Chinese medicine composition with whitening and freckle removing effects, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhang Qiuxia Inventor after: Zhang Xiaojuan Inventor before: Zhang Xiaojuan |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171229 |